Has results × Waldenstrom Macroglobulinemia × Bortezomib × Clear all
NCT01381692 2021-10-04

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Completed
9 enrolled 8 charts
NCT02037256 2021-05-10

Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma

Barbara Ann Karmanos Cancer Institute

Phase NA Completed
23 enrolled 8 charts